We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 20, 2020

Zanubrutinib for the Treatment of MYD88 Wild-Type Waldenström Macroglobulinemia

Blood advances


Additional Info

Disclosure statements are available on the authors' profiles:

Blood advances
Zanubrutinib for the Treatment of MYD88 Wild-Type Waldenström Macroglobulinemia: A Substudy of the Phase 3 ASPEN Trial
Blood Adv 2020 Dec 08;4(23)6009-6018, M Dimopoulos, RG Sanz, HP Lee, M Trneny, M Varettoni, S Opat, S D'Sa, RG Owen, G Cull, S Mulligan, J Czyz, JJ Castillo, M Motta, T Siddiqi, M Gironella Mesa, M Granell Gorrochategui, D Talaulikar, PL Zinzani, E Askari, S Grosicki, A Oriol, S Rule, J Kloczko, A Tedeschi, C Buske, V Leblond, J Trotman, WY Chan, J Michel, J Schneider, Z Tan, A Cohen, J Huang, CS Tam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading